An interventional study of Sedentary behavior reduction program on physical fitness. in Obesity (Disorder), sponsored by Hospital de Sao Sebastiao. Recruiting at 1 site in Portugal. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-23.
Sponsored by Hospital de Sao Sebastiao · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 68 studies in Obesity with a site in Portugal — 26 open to participants now, 32 under way, 12 of them phase 3. Obesity · Portugal.
Among the 68 studies in Obesity with a site in Portugal, this one is the 45th largest by planned enrollment of the 62 interventional ones that give a count, is one of 9 that started in 2026, is one of 35 with no phase, reaches primary completion later than 29 of the 31 other live ones, and was the 61st registered.
11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.
Browse Obesity studies →26 of the 68 studies in Obesity with a site in Portugal are open now. Recruiting first, the newest first:
Eli Lilly and Company · Sites in Portugal, United States, Belgium and 7 more countries
Ages 6–11
Novo Nordisk A/S · Sites in Portugal, United States, Greece and 3 more countries
Ages 18+
Novo Nordisk A/S · Sites in Portugal, United States, Argentina and 16 more countries
Ages 18+
Novo Nordisk A/S · Sites in Portugal, United States, Australia and 23 more countries
Ages 8–18
Amgen · Sites in Portugal, United States, Argentina and 32 more countries
Ages 18–99
A study can be open while its sites in Portugal have not opened yet or have stopped. Only those recruiting at a site in Portugal →
Of the 1,352 Obesity studies recruiting now, 382 (28%) set no upper age limit and 867 (64%) stop at 75 or younger; 169 take children under 18; 491 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
68 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 1 · Phase 3 23 · Phase 4 1
First in 2002; this study’s year is marked. 9 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 72 is close to the median of 67 across 9,043 interventional studies indexed under Obesity.
Median enrollment 150 across the 62 interventional studies, 4,103 across the 6 observational. Of the 27 that completed or were terminated, 7 (26%) have results posted.
This tab as a report to print or save as PDF → With an account.
26 of 68 have an industry lead sponsor. The 10 most frequent:
Hospital de Sao Sebastiao is the lead sponsor of 4 studies on the registry; 1 is open to participants now.
Hospital de Sao Sebastiao has 2 studies filed under Obesity — fewer than ten, so there is no comparison to draw.
4 of the studies in Obesity with a site in Portugal that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06672549Phase 3Eli Lilly and CompanyA Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040) | 2027-02 |
| NCT07745504Phase 3Novo Nordisk A/SA Research Study to Compare Two Different Versions of Injectable Cagrilintide and Placebo in People With Excess Body Weight | 2027-05-18 |
| NCT06771024Associação para o Desenvolvimento do Centro Académico de Investigação e Formação Biomédica do AlgarvCommunity Physical Exercise Program in Chronic Disease | 2026-12 |
| NCT07289529University of CoimbraCOMPASS 65+ - Community-based Physical Activity Snacks for Healthy Aging in Overweight and Obese Aged Adults | 2026-12 |
Add all 4 to your calendar (.ics) → With an account.
Among the 68 studies in Obesity with a site in Portugal, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Introduction: Sedentary behavior (SB) and insufficient physical activity (PA) interact to worsen physical fitness (PF), obesity-related complications and diseases (ORCD), and all-cause mortality in women with obesity. Replacing SB with low-intensity PA may improve PF and ameliorate ORCD, with potential lasting effects after bariatric surgery (BS). However, strong evidence on how PF influences BS outcomes and whether preoperative PA interventions can improve postoperative outcomes is lacking. The BARIMOV study aims to evaluate the effects of a structured sedentary behavior reduction program (SBRPro) on PF, investigate whether PF improvements influence BS outcomes, and explore potential mechanistic pathways by characterizing molecular adaptations in peripheral blood, skeletal muscle, and visceral adipose tissue (VAT).
Methods: BARIMOV is a prospective cohort study with five assessment time points. Adult women (≥18 years) with BMI 30-45 kg/m² scheduled for BS will be recruited (n = 72). At T0, participants will undergo a baseline assessment of PF - body composition, muscle strength, cardiorespiratory fitness - PA patterns, and ORCD screening. Participants will be instructed in the SBRPro and asked to maintain weekly PA diaries throughout the pre- and post-operative periods. At T1, adherence to SBRPro will be evaluated via diary review and PF reassessment, to enable participants' allocation into two adherence-based groups. At T2, during surgery, skeletal muscle and VAT biopsies will be collected for proteomic analysis to compare molecular adaptations of adherent and non-adherent groups. At T3 and T4, primary outcomes, including weight loss, body composition, ORCD, and quality of life (QoL), will be evaluated at 3±1 and 12±1 months postoperatively, respectively. Blood multiomics profiling will be performed at T0, T1, and T3 to explore dynamic changes in systemic metabolic pathways over time.
Conclusion: This study will determine whether PF improvement, achieved through structured SB reduction and PA engagement, is associated with better BS outcomes. By integrating clinical and molecular endpoints, the study will provide mechanistic insights into the pathways by which PF enhances BS outcomes and inform physical activity intervention strategies.
Phase 1: Enrollment and Multidisciplinary Education (T0) All participants will attend a group educational session (40 minutes) delivered by a multidisciplinary team (bariatric surgeon, exercise physiologist, dietitian) addressing: 1) overall education about the BS clinical process and surgery procedures, risks, advantages and disadvantages; 2) a comprehensive education on SB harms and health risks, and benefits of PA across the pre- and post-operative period; 3) practical strategies for reducing sedentary time (e.g., breaking up prolonged sitting or interrupting extended bouts); 4) PA safety, proper exercise execution, PA intensity management and progression strategies; 5) nutritional education for preoperative fitness and postoperative recovery; and 6) distribution of written materials (flyers and booklets) summarizing key take home contents delivered at the session.
Phase 2: Structured Preoperative Sedentary Behavior Reduction Program (T0 to T1) Participants will be asked to engage in the SBRPro, which includes aerobic and strength activities, in compliance with current PA guidelines. Flexibility to adapt the PA and exercise modality, duration, and intensity based on individual preferences, physical capacity, and available resources (home-based, gym-based, online platforms, or combined approaches) will be provided.
Phase 3: Structured Postoperative Sedentary Behavior Reduction Program (T2 to T4) Participants will be asked to resume SBRPro activities within the first week post-BS, adjusting the program for postoperative individual restrictions. A progressive increase in daily PA will be encouraged. For resistance exercises, participants will be advised to avoid heavy loading of incision/staple lines and to progress from light to moderate resistance as tolerated. Given the postoperative vulnerability, remote counseling will be provided as needed to enhance safety. The same weekly PA diary-based monitoring will be requested.
Physical Activity Monitoring and Adherence Assessment SBRPro adherence will be assessed through a structured weekly PA diary using a simple online form. The form will collect self-reported data on average daily sedentary time (minutes per day), total time spent in light, moderate, and vigorous physical activity (minutes per week), and the number of days per week engaged in resistance training. The form will also include a subsection addressing PA satisfaction/enjoyment (5-point Likert scale: 1, nothing fun; 2, little fun; 3, indifferent; 4, fun; 5, very fun), and any barriers or adverse events encountered. This weekly assessment will take place from baseline (the moment of enrolment in the study) until up to 12 months after surgery. For primary analyses, adherence subgroups, determined from the weekly PA diary, will be classified as having either an active or a sedentary lifestyle according to the most recent World Health Organization criteria. Individuals will be classified as physically active if they accumulate at least 150 minutes of moderate-intensity physical activity per week, and as sedentary if they do not meet this threshold. Participants with a sedentary lifestyle will serve as the de facto comparison group. This will enable evaluation of whether differential engagement with the SBRPro is associated with distinct clinical and functional outcomes.
During BS (T2), biopsies of abdominal skeletal muscle (transversus abdominis) and visceral adipose tissue (VAT) will be obtained under direct surgical visualization. Tissue fragments will be immediately processed and preserved at -80ºC for downstream proteomic analysis. Label-free quantitative proteomics, using the GeLC MS/MS approach, will be performed to identify differential protein expression patterns between adherence groups. Functional enrichment and pathway analyses will be conducted to characterize biological processes associated with preoperative SB reduction and PA engagement.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will be instructed in the sedentary behavior reduction program (SBRPro) and asked to maintain weekly physical activity diaries throughout the pre- and post-operative periods.
Behavioral: Sedentary behavior reduction program on physical fitness.
Non-adherence to the sedentary behavior reduction program.
The BARIMOV protocol incorporates this evidence through a structured, online sedentary behavior reduction program (SBRPro) that emphasizes substituting sedentary behavior with physical activity throughout the day.
Percentage of total weight loss (%TWL)
Primary clinical outcome evaluating the percentage of total weight loss, measuring weight in kilograms before and after surgery.
Time frame: Postoperative reassessment: T3 (3±1 months after surgery) and T4 (12±2 months after surgery).
Obesity-related complications and diseases (ORCD)
Pre- and post-operative status comparison through in-person clinical evaluations and routine laboratory analyses, including physical examination findings and longitudinal changes in pharmacological treatment requirements. ORCD will be assessed as a composite outcome including the presence of the following conditions, defined using a standardized criterion: Type 2 diabetes mellitus: HbA1c≥6.5% or use of glucose-lowering medication; Hypertension: systolic BP≥140 mmHg, diastolic BP≥90 mmHg, or antihypertensive treatment; Dyslipidemia: LDL-C, HDL-C, or triglycerides outside guideline thresholds or lipid-lowering therapy; Obstructive sleep apnea: confirmed by polysomnography \[AHI≥5 events/hour\]; Gastroesophageal reflux disease (GERD): heartburn and/or acid regurgitation occurring≥2 times per week or current use of proton pump inhibitors (PPIs) for reflux symptoms with prior physician diagnosis of GERD; Metabolic syndrome: defined according to NCEP ATP ΙΙΙ criteria.
Time frame: Preoperative assessments: T0 (6±3 months before surgery), and T1 (2 weeks±3 days before surgery). Postoperative reassessment: T3 (3±1 months after surgery) and T4 (12±2 months after surgery).
Changes in health-related quality of life (QoL)
Primary clinical outcome assessed by using the SF-12 (12-item Short Form Health Survey), a validated questionnaire.
Time frame: Preoperative assessments: T0 (6±3 months before surgery), and T1 (2 weeks±3 days before surgery). Postoperative reassessment: T3 (3±1 months after surgery) and T4 (12±2 months after surgery).
Body composition
Body composition \[fat mass (in kilograms and percentage), lean mass (in kilograms and percentage), muscle mass (in kilograms and percentage)\], measured via bioimpedance analysis (InBody 970 model, Biospace, Korea), will be combined to report the complete assessment of body composition.
Time frame: Preoperative assessments: T0 (6±3 months before surgery), and T1 (2 weeks±3 days before surgery). Postoperative reassessment: T3 (3±1 months after surgery) and T4 (12±2 months after surgery).
Muscle strength
Muscle strength (Kgf) will be assessed using handgrip (Jamar+, Lafayette Instrument Company, USA) and knee isometric strength tests (GripWise, Wisify Tech Solutions, Lda., Portugal). The handgrip strength evaluation method follows the Southampton protocol. Participants perform three trials in each hand (alternating sides), and the maximal grip score will be used. Assessment of isometric knee extensor strength will be performed with participants seated. The test involves three maximal voluntary isometric contractions. Participants will be instructed to hold the side of the plinth for stabilization. Constant verbal encouragement will be provided throughout the testing. A submaximal practice trial is performed for each leg to ensure the participant understands the required contraction. Three trials will be recorded for each knee, and the maximal strength value will be used.
Time frame: Preoperative assessments: T0 (6±3 months before surgery), and T1 (2 weeks±3 days before surgery). Postoperative reassessment: T3 (3±1 months after surgery) and T4 (12±2 months after surgery).
Cardiorespiratory fitness (CRF)
The estimated CRF (ml/min/kg) will be evaluated using the 2-minute step test (2MST). Briefly, the 2MST will be performed using a single, portable step that is 15 cm high. Participants are instructed to go up and down the step as many times as possible for two minutes (free cadence). The evaluator is responsible for counting up-and-down step cycles (UDS). The test will be performed according to the recommendations of the American Thoracic Society.
Time frame: Preoperative assessments: T0 (6±3 months before surgery), and T1 (2 weeks±3 days before surgery). Postoperative reassessment: T3 (3±1 months after surgery) and T4 (12±2 months after surgery).
Identification of proteomic differences in skeletal muscle and visceral adipose tissue associated with adherence at the time of surgery
Tissue fragments will be immediately processed and preserved at -80 ºC for downstream proteomic analysis. Label-free quantitative proteomics, using the GeLC MS/MS approach, will be performed to identify differential protein expression patterns between adherence groups.
Time frame: Intra-operative: T2
Longitudinal blood metabolomic adaptations
Plasma will be processed and stored at -80 ºC for metabolomic profiling. Circulating metabolomic profiling will be performed using proton nuclear magnetic resonance (1H-NMR) spectroscopy to evaluate longitudinal systemic metabolic adaptations across time points.
Time frame: Preoperative assessments: T0 (6±3 months before surgery), and T1 (2 weeks±3 days before surgery). Postoperative reassessment: T3 (3±1 months after surgery) and T4 (12±2 months after surgery).
Started Apr 2026 (actual). Primary completion is estimated for Oct 2030, 54 months after the start.
Of 3,697 non-industry interventional studies with no phase under Obesity, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's planned 54 months is above that.
Counting every sponsor, half of 3,861 studies reached it within 22 months; a quarter within 9 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Hospital de Sao Sebastiao